Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL1703 (BCMA-CD19 CAR-T) in RRMM with Extramedullary Infiltration
NCT07003555Phase 1Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- CAR-T Cells, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SL1703 in multiple myeloma (MM), sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-limiting toxicity at 30 days and Adverse events at 30 days. Started May 2025; status: recruiting.
02
Drugs
SL1703
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07003555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07003555.